Aprea Therapeutics Inc (APRE)

NASDAQ
0.950
-0.039(-3.90%)
After Hours
0.980
+0.030(+3.158%)
- Real-time Data
  • Volume:
    107,616
  • Day's Range:
    0.933 - 0.998
  • 52 wk Range:
    0.620 - 5.670

APRE Overview

Prev. Close
0.989
Day's Range
0.933-0.998
Revenue
-
Open
0.97
52 wk Range
0.62-5.67
EPS
-1.65
Volume
107,616
Market Cap
22.23M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
867,596
P/E Ratio
-0.584
Beta
0.294
1-Year Change
-73.97%
Shares Outstanding
23,401,846
Next Earnings Date
Nov 09, 2022
What is your sentiment on Aprea Thera?
or
Market is currently closed. Voting is open during market hours.

Aprea Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Aprea Therapeutics Inc Analysis

Aprea Therapeutics Inc Company Profile

Aprea Therapeutics Inc Company Profile

Employees
16

As of May 16, 2022, Aprea Therapeutics, Inc. was acquired by Atrin Pharmaceuticals LLC, in a reverse merger transaction. Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company’s lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); Phase I clinical trials for the treatment of relapsed/refractory TP53 mutant chronic lymphoid leukemia; and Phase I/II clinical trials in relapsed/refractory gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator, which is in Phase I clinical trials for the treatment of MDS and AML. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong SellStrong SellStrong Sell
Technical IndicatorsBuyNeutralStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell
  • this could be the end!
    0
    • w
      0
      • 'The emerging data for the combination of eprenetapopt and pembrolizumab in these difficult-to-treat patients is very encouraging,” said Dr. Haeseong Park of Washington University in St. Louis. “Particularly promising are tumor reductions in lung cancer patients who previously received I/O therapy, and the complete remission in a bladder cancer patient with prior chemotherapy exposure, which is rare. In addition, the clinical experience to-date suggests the combination is well-tolerated with adverse events readily managed with standard of care measures. The other investigators and I look forward to maturation of the data from this clinical trial as we seek to enroll and treat additional patients with this novel combination.'
        0
        • Thanks, do you have any other interesting stock to buy ? look at the premarket.. hope it keeps like this tomorrow opening session
          0
        • Kinross Gold Corp (KGC) , gold is extremely cheap in a must-have resource at all levels: geopolitical, industrial, coin backing, etc, etc
          0
        • only +5% in premarket...
          0
      • https://ir.aprea.com/static-files/47be1f37-ac5f-4302-8ce1-7ad5d2c88839
        0
        • It was today ~~ Date and Time: Monday, September 20, 2021; 17:35 – 17:40 CEST (11:35 – 11:40am EDT). At this moment APREA have not yet issued the content of the report, but already been. It must be a good report because not fallen too much
          0
          • I got it: Conclusions • Combination of eprenetapopt + pembrolizumab was safe and well-tolerated as evidenced by • Absence DLTs in the safety cohort • All grade AEs which were manageable with standard of care measures • 1 patient discontinued eprenetapopt due to AEs • Preliminary efficacy signal of disease reduction in 2 of 20 patients with NCSLC previously treated with IO therapy and 1/3 patients with IO-naïve bladder/urothelial cancer who achieved CR • Exploratory studies involving analyses of myeloid cells for inflammatory markers and immunosuppressive phenotype, and T cell phenotyping for exhaustion markers, are ongoing • The trial continues to enroll and treat patients
            0
        • ok I got 300 shares of this... bought at 4.98 based on a random comment from below. Trusting internet people... that's risky gambling
          0
          • maybe the +100% on a good day, today was terrible, but if u BUY 4,98 and sold about 5,5X it's a good profit in a very red day
            0
          • no way look the premarket now... will it hold until tomorrow ?
            0
          • who knows! what a joke! pre today was at sometime like +20% rude manipulation
            0
        • Why is it up 20% after market?
          0
          • not even in their website they announce any event
            0
          • ok you know what ? I bought some shares... let's see tomorrow if you were right. this is crazy, trusting somebody on the internet, lol
            0
          • sorry, just copy and paste the text I wrote in the night yesterday, so it's today, see the SEC filling
            0
        • BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16 – 21, 2021.
          0
          • Great recovery today
            0
            • Gang, I see bullish reversal happening today should be up day tomorrow.
              0
          • APRE price targets range from a high of $5.2to a $4.6 in the next 2 weeks.So buy investors buy!
            2